|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supporting Table 1**: Joinpoint incidence trends for top 15 cancers for all races/ethnicities combined by sex, 1999–2014 | | | | | | | | | | | | | | | | | | |
|  | Joinpoint Analyses (1999–2014)† | | | | | | | | | | | | | | | | | |
|  | Trend 1 | | | |  | Trend 2 | | | |  | Trend 3 | | | |  | AAPC‡ | | |
| Sex/Cancer Site or Type | Years | APC§ |  | P |  | Years | APC§ |  | P |  | Years | APC§ |  | P |  | 2010–2014 | | P |
| All sites|| |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Both sexes | 1999-2008 | -0.3 |  | .06 |  | 2008-2014 | -1.0 | ¶ | .001 |  |  |  |  |  |  | -1.0 | ¶ | .001 |
| Males | 1999-2008 | -0.6 | ¶ | .003 |  | 2008-2014 | -2.2 | ¶ | <.001 |  |  |  |  |  |  | -2.2 | ¶ | <.001 |
| Females | 1999-2014 | 0.0 |  | .96 |  |  |  |  |  |  |  |  |  |  |  | 0.0 |  | .96 |
| Children (ages 0–14) | 1999-2014 | 0.8 | ¶ | <.001 |  |  |  |  |  |  |  |  |  |  |  | 0.8 | ¶ | <.001 |
| Children (ages 0–19) | 1999-2014 | 0.8 | ¶ | <.001 |  |  |  |  |  |  |  |  |  |  |  | 0.8 | ¶ | <.001 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Top 17 cancers for males\*\* |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Prostate | 1999-2009 | -1.4 | ¶ | .01 |  | 2009-2014 | -7.6 | ¶ | <.001 |  |  |  |  |  |  | -7.6 | ¶ | <.001 |
| Lung and bronchus | 1999-2008 | -1.6 | ¶ | <.001 |  | 2008-2011 | -3.1 | ¶ | <.001 |  | 2011-2014 | -2.2 | ¶ | <.001 |  | -2.4 | ¶ | <.001 |
| Colon and rectum | 1999-2003 | -2.1 | ¶ | .001 |  | 2003-2012 | -3.4 | ¶ | <.001 |  | 2012-2014 | -0.5 |  | .75 |  | -1.9 | ¶ | .004 |
| Urinary bladder | 1999-2005 | -0.1 |  | .73 |  | 2005-2014 | -0.8 | ¶ | <.001 |  |  |  |  |  |  | -0.8 | ¶ | <.001 |
| Melanoma of the skin | 1999-2014 | 2.3 | ¶ | <.001 |  |  |  |  |  |  |  |  |  |  |  | 2.3 | ¶ | <.001 |
| Non-Hodgkin lymphoma | 1999-2005 | 0.8 | ¶ | .004 |  | 2005-2014 | -0.2 |  | .11 |  |  |  |  |  |  | -0.2 |  | .11 |
| Kidney and renal pelvis | 1999-2007 | 3.3 | ¶ | <.001 |  | 2007-2011 | -0.1 |  | .75 |  | 2011-2014 | 1.6 | ¶ | .007 |  | 1.1 | ¶ | .001 |
| Leukemia | 1999-2007 | 0.2 |  | .32 |  | 2007-2014 | 1.6 | ¶ | <.001 |  |  |  |  |  |  | 1.6 | ¶ | <.001 |
| Oral cavity and pharynx | 1999-2005 | -0.2 |  | .59 |  | 2005-2014 | 1.3 | ¶ | <.001 |  |  |  |  |  |  | 1.3 | ¶ | <.001 |
| Pancreas | 1999-2014 | 1.0 | ¶ | <.001 |  |  |  |  |  |  |  |  |  |  |  | 1.0 | ¶ | <.001 |
| Liver and intrahepatic bile duct | 1999-2009 | 4.4 | ¶ | <.001 |  | 2009-2014 | 2.8 | ¶ | <.001 |  |  |  |  |  |  | 2.8 | ¶ | <.001 |
| Stomach | 1999-2007 | -1.8 | ¶ | <.001 |  | 2007-2014 | -0.3 |  | .13 |  |  |  |  |  |  | -0.3 |  | .13 |
| Myeloma | 1999-2007 | 1.2 | ¶ | <.001 |  | 2007-2014 | 2.5 | ¶ | <.001 |  |  |  |  |  |  | 2.5 | ¶ | <.001 |
| Esophagus | 1999-2007 | 0.3 |  | .26 |  | 2007-2014 | -1.6 | ¶ | <.001 |  |  |  |  |  |  | -1.6 | ¶ | <.001 |
| Brain and other nervous system | 1999-2014 | -0.2 | ¶ | .003 |  |  |  |  |  |  |  |  |  |  |  | -0.2 | ¶ | .003 |
| Thyroid | 1999-2009 | 6.8 | ¶ | <.001 |  | 2009-2014 | 2.4 | ¶ | <.001 |  |  |  |  |  |  | 2.4 | ¶ | <.001 |
| Larynx | 1999-2014 | -2.3 | ¶ | <.001 |  |  |  |  |  |  |  |  |  |  |  | -2.3 | ¶ | <.001 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

Supporting Table 1 (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Joinpoint Analyses (1999–2014)† | | | | | | | | | | | | | | | | | |
|  | Trend 1 | | | |  | Trend 2 | | | |  | Trend 3 | | | |  | AAPC‡ | | |
| Sex/Cancer Site or Type | Years | APC§ |  | P |  | Years | APC§ |  | P |  | Years | APC§ |  | P |  | 2010–2014 | | P |
| Top 18 cancers for females\*\* |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Breast | 1999-2004 | -2.2 | ¶ | <.001 |  | 2004-2014 | 0.4 | ¶ | .008 |  |  |  |  |  |  | 0.4 | ¶ | .008 |
| Lung and bronchus | 1999-2006 | 0.7 | ¶ | <.001 |  | 2006-2014 | -1.2 | ¶ | <.001 |  |  |  |  |  |  | -1.2 | ¶ | <.001 |
| Colon and rectum | 1999-2006 | -2.0 | ¶ | <.001 |  | 2006-2012 | -3.4 | ¶ | <.001 |  | 2012-2014 | -0.1 |  | .94 |  | -1.7 | ¶ | .004 |
| Corpus and uterus, NOS | 1999-2003 | -0.6 |  | .13 |  | 2003-2014 | 1.2 | ¶ | <.001 |  |  |  |  |  |  | 1.2 | ¶ | <.001 |
| Thyroid | 1999-2009 | 7.4 | ¶ | <.001 |  | 2009-2014 | 1.9 | ¶ | <.001 |  |  |  |  |  |  | 1.9 | ¶ | <.001 |
| Melanoma of the skin | 1999-2005 | 3.8 | ¶ | <.001 |  | 2005-2014 | 1.2 | ¶ | .002 |  |  |  |  |  |  | 1.2 | ¶ | .002 |
| Non-Hodgkin lymphoma | 1999-2004 | 0.8 | ¶ | .03 |  | 2004-2014 | -0.4 | ¶ | .002 |  |  |  |  |  |  | -0.4 | ¶ | .002 |
| Ovary|| | 1999-2014 | -1.6 | ¶ | <.001 |  |  |  |  |  |  |  |  |  |  |  | -1.6 | ¶ | <.001 |
| Leukemia | 1999-2005 | 0.3 |  | .42 |  | 2005-2014 | 1.4 | ¶ | <.001 |  |  |  |  |  |  | 1.4 | ¶ | <.001 |
| Kidney and renal pelvis | 1999-2006 | 3.9 | ¶ | <.001 |  | 2006-2014 | 0.4 | ¶ | .03 |  |  |  |  |  |  | 0.4 | ¶ | .03 |
| Pancreas | 1999-2014 | 1.1 | ¶ | <.001 |  |  |  |  |  |  |  |  |  |  |  | 1.1 | ¶ | <.001 |
| Urinary bladder | 1999-2014 | -0.8 | ¶ | <.001 |  |  |  |  |  |  |  |  |  |  |  | -0.8 | ¶ | <.001 |
| Cervix uteri | 1999-2003 | -3.9 | ¶ | <.001 |  | 2003-2014 | -1.0 | ¶ | <.001 |  |  |  |  |  |  | -1.0 | ¶ | <.001 |
| Oral cavity and pharynx | 1999-2004 | -0.6 |  | .18 |  | 2004-2014 | 0.8 | ¶ | <.001 |  |  |  |  |  |  | 0.8 | ¶ | <.001 |
| Myeloma | 1999-2007 | 0.4 | ¶ | .03 |  | 2007-2010 | 3.6 | ¶ | .02 |  | 2010-2014 | 1.6 | ¶ | .003 |  | 1.6 | ¶ | .003 |
| Brain and other nervous system | 1999-2007 | 0.2 |  | .33 |  | 2007-2014 | -0.7 | ¶ | .008 |  |  |  |  |  |  | -0.7 | ¶ | .008 |
| Stomach | 1999-2008 | -1.1 | ¶ | <.001 |  | 2008-2014 | 0.1 |  | .77 |  |  |  |  |  |  | 0.1 |  | .77 |
| Liver and intrahepatic bile duct | 1999-2001 | -2.4 |  | .45 |  | 2001-2014 | 3.8 | ¶ | <.001 |  |  |  |  |  |  | 3.8 | ¶ | <.001 |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Abbreviations: AAPC, average annual percent change; APC, annual percent change; NOS, not otherwise specified. |  |  |  |  |  |  |
| \* Source: NPCR and SEER areas reported by NAACCR as meeting high-quality incidence data standards for the specified time periods. |  |  |  |  |  |  |
| †  Joinpoint models with up to two joinpoints are based on rates per 100,000 persons age standardized to the 2000 US standard population (19 age groups - Census P25–1130).  Joinpoint Regression Program, Version 4.4.0.0 January 2017, Statistical Research and Applications Branch, National Cancer Institute. | | | | | | |
| ‡  AAPC is the average annual percent change and is a weighted average of the annual percent change (APCs) over the fixed interval 2010-2014 using the underlying Joinpoint model  for the period of 1999-2014. |  |  |  |  |  |  |
| § The APC is based on rates that were age-adjusted to the 2000 US standard population (19 age groups, Census publication p25–1130). |  |  |  |  |  |  |
| || All sites excludes myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors. |  |  |  |  |  |  |
| ¶  The APC or AAPC is statistically significantly different from zero (2-sided *t* test; *P* < .05). |  |  |  |  |  |  |
| \*\* Cancers are listed in descending rank order of sex-specific, age-adjusted incidence rates for 2010-2014 for all racial and ethnic groups combined (using data from the National  Program of Cancer Registries [NPCR] and SEER Program areas reported by the North American Association of Central Cancer Registries [NAACCR] as meeting high-quality incidence  data standards for 1999–2014). More than 15 cancers may appear under men and women to include the top 15 cancers in each racial and ethnic group. | | | | | | |
| Registries included in the Joinpoint models (1999-2014) for all races/ethnicities (42 states): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware,  Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nebraska, New Hampshire,  New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Vermont, Washington, West Virginia,  Wisconsin, Wyoming. | | | | | | |

**Supporting Table 2**. Joinpoint mortality trends for the most common cancers, all races and ethnicities combined, by sex, 1999-2015\*

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Joinpoint Analyses (1999–2015)† | | | | | | | | | | | | | | | | | | | | | | | |
|  | Trend 1 | | | |  | Trend 2 | | | |  | Trend 3 | | | |  | Trend 4 | | | |  | AAPC‡ | | |
| Sex/Cancer Site or Type | Years | APC§ |  | P |  | Years | APC§ |  | P |  | Years | APC§ |  | P |  | Years | APC§ |  | P |  | 2011-2015 | | P |
| All sites |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Both sexes | 1999-2001 | -1.0 | || | .01 |  | 2001-2015 | -1.5 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | -1.5 | || | <.001 |
| Males | 1999-2015 | -1.8 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -1.8 | || | <.001 |
| Females | 1999-2002 | -0.9 | || | .001 |  | 2002-2015 | -1.4 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | -1.4 | || | <.001 |
| Children (ages 0-14) | 1999-2015 | -1.5 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -1.5 | || | <.001 |
| Children (ages 0-19) | 1999-2015 | -1.6 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -1.6 | || | <.001 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Top 18 cancers for males¶ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Lung and Bronchus | 1999-2005 | -1.8 | || | <.001 |  | 2005-2012 | -3.0 | || | <.001 |  | 2012-2015 | -4.0 | || | <.001 |  |  |  |  |  |  | -3.8 | || | <.001 |
| Prostate | 1999-2013 | -3.5 | || | <.001 |  | 2013-2015 | -0.9 |  | .62 |  |  |  |  |  |  |  |  |  |  |  | -2.2 | || | .01 |
| Colon and Rectum | 1999-2002 | -2.0 | || | .001 |  | 2002-2005 | -4.1 | || | .001 |  | 2005-2015 | -2.5 | || | <.001 |  |  |  |  |  |  | -2.5 | || | <.001 |
| Pancreas | 1999-2015 | 0.2 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.2 | || | <.001 |
| Liver and Intrahepatic Bile Duct | 1999-2013 | 2.7 | || | <.001 |  | 2013-2015 | 0.5 |  | .73 |  |  |  |  |  |  |  |  |  |  |  | 1.6 | || | .03 |
| Leukemia | 1999-2013 | -0.9 | || | <.001 |  | 2013-2015 | -3.5 | || | .003 |  |  |  |  |  |  |  |  |  |  |  | -2.2 | || | <.001 |
| Urinary Bladder | 1999-2013 | 0.0 |  | .52 |  | 2013-2015 | -1.4 |  | .22 |  |  |  |  |  |  |  |  |  |  |  | -0.7 |  | .21 |
| Non-Hodgkin Lymphoma | 1999-2006 | -2.9 | || | <.001 |  | 2006-2015 | -2.0 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | -2.0 | || | <.001 |
| Esophagus | 1999-2005 | 0.4 |  | .12 |  | 2005-2015 | -1.1 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | -1.1 | || | <.001 |
| Kidney and Renal Pelvis | 1999-2001 | 2.7 | || | .02 |  | 2001-2006 | -1.4 | || | .001 |  | 2006-2015 | -0.5 | || | <.001 |  |  |  |  |  |  | -0.5 | || | <.001 |
| Brain and Other Nervous System | 1999-2006 | -1.3 | || | <.001 |  | 2006-2015 | 0.5 | || | .01 |  |  |  |  |  |  |  |  |  |  |  | 0.5 | || | .01 |
| Stomach | 1999-2011 | -3.2 | || | <.001 |  | 2011-2015 | -1.6 | || | .01 |  |  |  |  |  |  |  |  |  |  |  | -1.6 | || | .01 |
| Myeloma | 1999-2015 | -0.9 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -0.9 | || | <.001 |
| Melanoma of the Skin | 1999-2009 | 0.9 | || | <.001 |  | 2009-2013 | -0.9 |  | .31 |  | 2013-2015 | -5.0 | || | .01 |  |  |  |  |  |  | -3.0 | || | .001 |
| Oral Cavity and Pharynx | 1999-2009 | -1.2 | || | <.001 |  | 2009-2015 | 1.0 | || | .04 |  |  |  |  |  |  |  |  |  |  |  | 1.0 | || | .04 |
| Larynx | 1999-2015 | -2.5 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -2.5 | || | <.001 |
| Non-Melanoma Skin | 1999-2008 | 0.2 |  | .68 |  | 2008-2015 | 2.8 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | 2.8 | || | <.001 |
| Soft Tissue including Heart | 1999-2002 | -2.5 |  | .09 |  | 2002-2015 | 0.8 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | 0.8 | || | <.001 |

Supporting Table 2 (cont.)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Joinpoint Analyses (1999–2015)† | | | | | | | | | | | | | | | | | | | | | | | |
|  | Trend 1 | | | |  | Trend 2 | | | |  | Trend 3 | | | |  | Trend 4 | | | |  | AAPC‡ | | |
| Sex/Cancer Site or Type | Years | APC§ |  | P |  | Years | APC§ |  | P |  | Years | APC§ |  | P |  | Years | APC§ |  | P |  | 2011–2015 | | P |
| Top 20 cancers for females¶ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Lung and Bronchus | 1999-2002 | 1.0 | || | .04 |  | 2002-2007 | -0.8 | || | .02 |  | 2007-2012 | -1.9 | || | <.001 |  | 2012-2015 | -2.6 | || | .001 |  | -2.4 | || | <.001 |
| Breast | 1999-2003 | -1.5 | || | <.001 |  | 2003-2007 | -2.4 | || | <.001 |  | 2007-2015 | -1.6 | || | <.001 |  |  |  |  |  |  | -1.6 | || | <.001 |
| Colon and Rectum | 1999-2015 | -2.7 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -2.7 | || | <.001 |
| Pancreas | 1999-2015 | 0.2 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.2 | || | <.001 |
| Ovary | 1999-2003 | 0.6 |  | .15 |  | 2003-2015 | -2.3 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | -2.3 | || | <.001 |
| Leukemia | 1999-2013 | -1.2 | || | <.001 |  | 2013-2015 | -3.5 | || | .03 |  |  |  |  |  |  |  |  |  |  |  | -2.3 | || | .001 |
| Corpus and Uterus, NOS | 1999-2008 | 0.3 |  | .14 |  | 2008-2015 | 1.9 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | 1.9 | || | <.001 |
| Non-Hodgkin Lymphoma | 1999-2005 | -3.6 | || | <.001 |  | 2005-2015 | -2.7 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | -2.7 | || | <.001 |
| Liver and Intrahepatic Bile Duct | 1999-2008 | 1.5 | || | <.001 |  | 2008-2015 | 2.7 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | 2.7 | || | <.001 |
| Brain and Other Nervous System | 1999-2006 | -1.3 | || | .001 |  | 2006-2015 | 0.5 | || | .03 |  |  |  |  |  |  |  |  |  |  |  | 0.5 | || | .03 |
| Myeloma | 1999-2009 | -2.1 | || | <.001 |  | 2009-2015 | 0.0 |  | .92 |  |  |  |  |  |  |  |  |  |  |  | 0.0 |  | .92 |
| Kidney and Renal Pelvis | 1999-2001 | 2.8 |  | .33 |  | 2001-2015 | -1.4 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | -1.4 | || | <.001 |
| Stomach | 1999-2008 | -2.9 | || | <.001 |  | 2008-2015 | -1.8 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | -1.8 | || | <.001 |
| Cervix Uteri | 1999-2004 | -3.2 | || | <.001 |  | 2004-2015 | -0.7 | || | .001 |  |  |  |  |  |  |  |  |  |  |  | -0.7 | || | .001 |
| Urinary Bladder | 1999-2015 | -0.5 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -0.5 | || | <.001 |
| Melanoma of the Skin | 1999-2012 | -0.4 |  | .06 |  | 2012-2015 | -3.4 |  | .07 |  |  |  |  |  |  |  |  |  |  |  | -2.6 | || | .04 |
| Esophagus | 1999-2015 | -1.6 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -1.6 | || | <.001 |
| Oral Cavity and Pharynx | 1999-2015 | -1.3 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -1.3 | || | <.001 |
| Soft Tissue including Heart | 1999-2002 | -2.1 | || | .03 |  | 2002-2015 | 0.1 |  | .11 |  |  |  |  |  |  |  |  |  |  |  | 0.1 |  | .11 |
| Gallbladder | 1999-2015 | -1.3 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -1.3 | || | <.001 |

|  |
| --- |
| Abbreviations: AAPC, average annual percent change; APC, annual percent change; NCHS, National Center for Health Statistics; NOS, not otherwise specified. |
| \* Source: NCHS public-use data file for the total US, 1975–2015. |
| † Joinpoint models with up to three joinpoints are based on rates per 100,000 persons age standardized to the 2000 US standard population (19 age groups - Census P25–1130). Joinpoint Regression Program, Version 4.5.0.1. June 2017, Statistical Research and Applications Branch, National Cancer Institute. |
| ‡ AAPC is the average annual percent change and is a weighted average of the annual percent change (APCs) over the fixed interval 2011-2015 using the underlying Joinpoint model for the period of 1999-2015. |
| § The APC is based on rates that were age-adjusted to the 2000 US standard population (19 age groups, Census publication p25–1130). |
| || The APC or AAPC is statistically significantly different from zero (2-sided t test; P <.05). |
| ¶ Cancers are listed in descending rank order of sex-specific, age-adjusted death rates for 2011-2015 for all racial and ethnic groups combined. More than 15 cancers may appear under men and women to include the top 15 cancers in each racial and ethnic group. |